Publications by authors named "Janet Lasher"

Claim this Profile
A
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
Yong-Rong Lai, Maria Domenica Cappellini, Yesim Aydinok, John Porter, Zeynep Karakas, Janet Lasher

Am J Hematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Mathias J Rummel, Ann Janssens, David MacDonald, Mary-Margaret Keating, Jan M Zaucha, Janet Lasher

Br J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.
David G Maloney, Michinori Ogura, Noriko Fukuhara, Jaclyn Davis, Janet Lasher

Blood Adv· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Stephan Petersenn, Jens Bollerslev, Ayman M Arafat, Jochen Schopohl, Omar Serri, Janet Lasher

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Xia Chen, Guoxiang Shen, Ji Jiang, Hongzhong Liu, Ke Hu, Janet Lasher

Clin Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Stephan Petersenn, Ke Hu, Mario Maldonado, Yilong Zhang, Janet Lasher

Clin Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Roelf Valkema, Stanislas A Pauwels, Larry K Kvols, Dik J Kwekkeboom, Francois Jamar, Janet Lasher

J Nucl Med· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis